Shamburg News · 8-K filed Nov 13, 2026, 4:59 PM EST

Evofem Biosciences Reports Third Quarter 2026 Results With $0.9 Million Net Income

EVFM · Evofem Biosciences, Inc.

  • Earnings
  • Financial statements
  • Materiality: high

Evofem Biosciences reported third quarter 2026 product sales, net, of $4.6 million, down from $5.0 million in the prior year period. Income from operations was $0.7 million, compared with $1.0 million in Q3 2025. Net income attributable to common stockholders was $0.9 million, or $0.01 per basic share, versus a net loss of $1.7 million in the prior year quarter.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-051806.

Written from the filing by Shamburg Markets. Figures are as reported by the company.